June 25-28, the pharmaceutical health industry Symbiosis conference was held in South Taihu Lake, Zhejiang Province. The "2023 China Pharmaceutical Industry Top 100 Series List" and "2024 China Pharmaceutical Brand List" were released at the meeting. Qidu Pharmaceutical has been listed in the TOP100 list of Chinese chemical pharmaceutical enterprises for 12 consecutive years, ranking 36th. Eqing ®- Pivastatin calcium tablets was named as the "2024 China Pharmaceutical Brand List" primary terminal award brand.

The theme of the conference is "Progressive · New Bureau", the positioning is "professional and connection", and the brand name card is "strategy prediction, professional empowerment, information insight, brand connection", and the resources in various fields of the pharmaceutical and health industry are aggregated. It has attracted the participation of government departments, association units, chain pharmacies, pharmaceutical companies, terminals inside and outside the hospital, innovation and technology platforms, CXO companies, pharmaceutical industrial parks, and media inside and outside the industry. The conference is committed to interpreting the pharmaceutical and health industry policy, insight into the pharmaceutical market changes, share professional business concepts, introduce development and innovation models for the industry, commend the double hundred benchmarking enterprises, build a resource connection platform to promote the docking and trading of achievement projects in various fields of the pharmaceutical industry, and promote the continuous innovation and upgrading of the pharmaceutical and health industry.

In recent years, Qidu Pharmaceutical has actively responded to the national call for high-quality development of the real economy and biomedical industry, and constantly promoted new breakthroughs in enterprise development. First, the project supports strong investment, actively uses modern concepts and high-tech to transform and upgrade traditional industries, and the per capita production capacity and production speed have doubled. Among them, the large-scale injection production project with an annual output of 1 billion bottles is the digital workshop in Shandong Province, which fully applies the "intelligent digital twin system". Through the efficient collaboration of intelligent digital control system and advanced technology and equipment, labor productivity has been greatly improved, the per capita production capacity has been increased by nearly 3 times, the production speed has been increased by 3 times, and the production cost and energy consumption have also decreased to varying degrees. It is an injection production project with the largest production scale, the most advanced technology and the highest digital level in China. The intelligent production project with an annual output of 10 billion tablets of oral preparations under construction not only covers the five mainstream dosage forms, but also develops three characteristic production lines, including the independent production line of antibiotics, the independent production line of anti-tumor drugs, and the independent production line of hormones with glucocorticoids as the main development direction. Second, science and technology lead to increase the momentum, always adhere to the combination of production, research and independent research and development of the "two legs to walk" R & D policy, on the one hand, with well-known pharmaceutical companies at home and abroad, universities and scientific research institutions to establish a long-term stable cooperative relationship, through the cooperation with the Chinese Academy of Sciences Qingdao Institute of Bioenergy, East China University of Science and Technology and other institutions, successfully developed the L-carnitine bioenzyme green synthesis process, Jointly with the R&D team of Tianjin University, we broke through the foreign technology monopoly of "preparation method and device of large particle sodium bicarbonate", which significantly improved the competitiveness of domestic pharmaceutical apis in the global market. Recently, it cooperated with Peking University to build an innovative pharmaceutical laboratory, and reached a technical cooperation agreement with Japan's Tachiyama Chemical. On the other hand, relying on the national enterprise technology center, postdoctoral research stations and provincial key laboratories and other research and development platforms to improve independent research and development capabilities, focus on special process products, and strive to achieve breakthroughs in the development of generic drug products; Focus on the dosage forms and products with higher technical barriers, and strive to make strong breakthroughs in the production conditions of high-end preparations; Focus on the special process of raw materials green substitution and bottleneck technology, and strive to make a strong breakthrough in the development and application of new processes and break the monopoly.

In the future, Qidu Pharmaceutical will always uphold the brand concept of "working together to protect healthy China", abide by the corporate purpose of "quality enterprise, science and technology enterprise, talent enterprise", continue to make efforts in project construction and scientific research and development, continue to create scale advantages, continue to introduce more subversive, efficient and excellent quality drugs in the pharmaceutical field, and inject sufficient impetus for the progress of medical and health care. To protect people's health to contribute to the wisdom and strength of medicine people.